Blaize Holdings, Inc. (Nasdaq: BZAI, Nasdaq: BZAIW) (“Blaize,” the “Company,” “we,” “our,” or “us”), a leader in programmable, energy-efficient AI computing, and NeoTensr, a hardware and software system integrator, today announced an up to $50.0 million contract to jointly develop and deploy co-branded AI edge data center infrastructure targeting the rapidly growing compute market across the broader Asia Pacific region.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has received Clinical Trial Application (CTA) approval to expand the ongoing global ELIMINATE-B clinical trial of PBGENE-HBV. The regulatory authorization will allow Precision to initiate important hepatitis B clinical trial sites in France and Romania. This expansion broadens the trial’s global footprint deeper into Europe, adding to existing clinical trial sites in the United Kingdom, Moldova, New Zealand, Hong Kong and the United States.

Capstone Holding Corp. (NASDAQ: CAPS), a tech-enabled building products distribution platform, today announced financial and operating results for the fourth quarter and full year ended December 31, 2025.

Creative Media & Community Trust Corporation (NASDAQ: CMCT) (“we”, “our”, “CMCT” or the “Company”) announced today that its Board of Directors has approved a reverse stock split of CMCT common stock at a ratio of one-for-ten (the “Reverse Stock Split”).